These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 31735750)
1. [HMGB1 as a target for prevention of chemotherapy-induced peripheral neuropathy]. Kawabata A; Tsubota M; Sekiguchi F; Tsujita R Nihon Yakurigaku Zasshi; 2019; 154(5):236-240. PubMed ID: 31735750 [TBL] [Abstract][Full Text] [Related]
2. Role of HMGB1 in Chemotherapy-Induced Peripheral Neuropathy. Sekiguchi F; Kawabata A Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396481 [TBL] [Abstract][Full Text] [Related]
3. Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin/thrombomodulin system in rodents: negative impact of anticoagulants. Tsubota M; Fukuda R; Hayashi Y; Miyazaki T; Ueda S; Yamashita R; Koike N; Sekiguchi F; Wake H; Wakatsuki S; Ujiie Y; Araki T; Nishibori M; Kawabata A J Neuroinflammation; 2019 Oct; 16(1):199. PubMed ID: 31666085 [TBL] [Abstract][Full Text] [Related]
4. Caspase-Dependent HMGB1 Release from Macrophages Participates in Peripheral Neuropathy Caused by Bortezomib, a Proteasome-Inhibiting Chemotherapeutic Agent, in Mice. Tsubota M; Miyazaki T; Ikeda Y; Hayashi Y; Aokiba Y; Tomita S; Sekiguchi F; Wang D; Nishibori M; Kawabata A Cells; 2021 Sep; 10(10):. PubMed ID: 34685531 [TBL] [Abstract][Full Text] [Related]
5. Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats. Nishida T; Tsubota M; Kawaishi Y; Yamanishi H; Kamitani N; Sekiguchi F; Ishikura H; Liu K; Nishibori M; Kawabata A Toxicology; 2016 Jul; 365():48-58. PubMed ID: 27474498 [TBL] [Abstract][Full Text] [Related]
6. Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies. Miyamoto T; Domoto R; Sekiguchi F; Kamaguchi R; Nishimura R; Matsuno M; Tsubota M; Fujitani M; Hatanaka S; Koizumi Y; Wang D; Nishibori M; Kawabata A J Pharmacol Sci; 2022 Mar; 148(3):315-325. PubMed ID: 35177211 [TBL] [Abstract][Full Text] [Related]
7. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Kuriyama A; Endo K Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005 [TBL] [Abstract][Full Text] [Related]
8. Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy. Bakogeorgos M; Georgoulias V Expert Rev Anticancer Ther; 2017 Nov; 17(11):1045-1060. PubMed ID: 28868935 [TBL] [Abstract][Full Text] [Related]
9. Promoting AMPK/SR-A1-mediated clearance of HMGB1 attenuates chemotherapy-induced peripheral neuropathy. Yang X; Jia R; Hu F; Fan W; Lin T; Zhang X; Xu C; Ruan S; Jiang C; Li Y; Pan C; Yang Y; Hu L; Chen Q; Liu WT Cell Commun Signal; 2023 May; 21(1):99. PubMed ID: 37143083 [TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy-induced peripheral neuropathy; impact on quality of life]. Scheel A; Beijers AJ; Mols F; Faber CG; Vreugdenhil G Ned Tijdschr Geneeskd; 2014; 158():A7455. PubMed ID: 25315326 [TBL] [Abstract][Full Text] [Related]
11. Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms. Hu LY; Mi WL; Wu GC; Wang YQ; Mao-Ying QL Curr Neuropharmacol; 2019; 17(2):184-196. PubMed ID: 28925884 [TBL] [Abstract][Full Text] [Related]
12. Development and validation of the comprehensive assessment scale for chemotherapy-induced peripheral neuropathy in survivors of cancer. Kanda K; Fujimoto K; Mochizuki R; Ishida K; Lee B BMC Cancer; 2019 Sep; 19(1):904. PubMed ID: 31506070 [TBL] [Abstract][Full Text] [Related]
13. Role for Drug Transporters in Chemotherapy-Induced Peripheral Neuropathy. Stage TB; Hu S; Sparreboom A; Kroetz DL Clin Transl Sci; 2021 Mar; 14(2):460-467. PubMed ID: 33142018 [TBL] [Abstract][Full Text] [Related]
14. Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Hoshino N; Ganeko R; Hida K; Sakai Y Int J Clin Oncol; 2018 Jun; 23(3):434-442. PubMed ID: 29270698 [TBL] [Abstract][Full Text] [Related]
15. Updating your peripheral neuropathy "know-how". Marrs J; Newton S Clin J Oncol Nurs; 2003; 7(3):299-303. PubMed ID: 12793336 [TBL] [Abstract][Full Text] [Related]
16. Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial. Clavo B; Martínez-Sánchez G; Rodríguez-Esparragón F; Rodríguez-Abreu D; Galván S; Aguiar-Bujanda D; Díaz-Garrido JA; Cañas S; Torres-Mata LB; Fabelo H; Téllez T; Santana-Rodríguez N; Fernández-Pérez L; Marrero-Callico G Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802143 [TBL] [Abstract][Full Text] [Related]
18. Potential application of the Kampo medicine goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy. Cascella M; Muzio MR J Integr Med; 2017 Mar; 15(2):77-87. PubMed ID: 28285612 [TBL] [Abstract][Full Text] [Related]
19. Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy. Kelley MR; Wikel JH; Guo C; Pollok KE; Bailey BJ; Wireman R; Fishel ML; Vasko MR J Pharmacol Exp Ther; 2016 Nov; 359(2):300-309. PubMed ID: 27608656 [TBL] [Abstract][Full Text] [Related]
20. Prevention and treatment of chemotherapy-induced peripheral neuropathy. Piccolo J; Kolesar JM Am J Health Syst Pharm; 2014 Jan; 71(1):19-25. PubMed ID: 24352178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]